Shares of Protalix Biotherapeutics were up in trading after the company announced the Phase III BRIDGE study met key objectives in treating Fabry Disease.
https://www.pharmalive.com/wp-content/uploads/2020/12/Protalixs-Fabry-Disease-Treatment-Hits-the-Mark-in-Phase-III-Switch-Over-Study-BioSpace-12-30-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-12-30 11:13:382020-12-30 11:14:51Fabry Disease Treatment Hits Mark in Phase III Switch-Over Study